Dr. Joseph Pater receives inaugural Canadian Cancer Society Lifetime Contribution Prize

Dr. Joseph Pater receives inaugural Canadian Cancer Society Lifetime Contribution Prize

Dr. Joseph Pater, is the recipient of the Canadian Cancer Society Lifetime Contribution Prize, a new honour from the Canadian Cancer Society (CCS). The award recognizes an esteemed Canadian investigator whose contributions, vision, and leadership, have enhanced the Canadian cancer research landscape to significantly benefit the lives of people with cancer.

More >>
 
Dr. Elizabeth Eisenhauer by Bernard Clark

Dr. Elizabeth Eisenhauer presented with 2021 Canada Gairdner Wightman Award

Dr. Elizabeth Eisenhauer, former CCTG IND Program Director and CCTG Interim Group Director, has been presented with the 2021 Canada Gairdner Wightman Award, for her dedication to transforming the fields of cancer clinical trials and cancer drug delivery.

More >>
 

MAC15 RxPONDER trial presented at the San Antonio Breast Cancer Symposium

Postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low, do not benefit from chemotherapy when it is added to hormone therapy, according to initial results from the MAC15 RxPONDER trial presented at the 2020 San Antonio Breast Cancer Symposium.

More >>
 
SC24 Practicing changing trial results presented at the ASTRO 2020 meeting

Treating spinal lesions with fewer, higher doses of radiation reduces pain more effectively

The results show that using fewer and higher doses of high-precision radiation therapy is a more effective approach for treating painful spinal tumors than conventional radiation therapy. More than twice as many patients treated with stereotactic body radiation therapy (SBRT) reported an enduring, complete reduction in pain, compared to those treated with conventional radiation.

More >>
 

Planned trials

CLC3

Venetoclax and Obinutuzumab vs DeLayed Therapy with VEnetoclax and Obinutuzumab in Asymptomatic High-Risk Patients with CLL/SLL

EN10

Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (TAPER)

HD11

Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma

HN11

SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)

I240

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)

More >>

MA41

De-Escalation of ChemotheRapy in HER-2 positive, EStrogen reCEptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 blOckade (DECRESCENDO)

MAC27

COMPASSHER2 Residual Disease, A Double-Blinded, Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

MYC2

Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration

More >>

Recently activated

CO29

Tumor DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer (DYNAMIC III)

More >>

CXC2

Radiation Therapy and Cisplatin Alone or in Combination with Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

More >>

PAC3

Perioperative vs Adjuvant Chemotherapy for Resectable Pancreatic Cancer

More >>

SR7

Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)

More >>

Asking the right questions

Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.  

“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”

More >>
 
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 

Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide

Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.

More >>
 
Pancreatic cancer patient Susan Stewart with her family, she enrolled in the CCTG PA.7 immunotherapy and chemotherapy trial

New pancreatic cancer trial provides hope to BC family

An innovative clinical trial underway across Canada is providing new hope to a B.C. family braving pancreatic cancer – the deadliest cancer facing Canadians today.

More >>
 

Publications

Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients

Translational Lung Cancer Research 10: 826 - 838, 21 F
Fung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;

More >>

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

The Lancet 397: 695 - 703, 2021
Pal SK;Tangen C;Thompson IM;Balzer-Haas N;George DJ;Heng DYC;Shuch B;Stein M;Tretiakova M;Humphrey P;Adeniran A;Narayan V;Bjarnason GA;Vaishampayan U;Alva A;Zhang T;Cole S;Plets M;Wright J;Lara PN;

More >>

Reassessing the Net Benefit of Cancer Drugs With Evolution of Evidence Using the ASCO Value Framework (ONLINE)

Journal of the National Comprehensive Cancer Network J Natl Compr Canc Netw : 1 - 6, 2021
Seanthel DS;Noah W;Bishal G;Vanessa SA;Amanda PR;Louis E;Matthew CC;Kelvin KC;

More >>

Minimization of resource utilization data collected within cost-effectiveness analyses conducted alongside Canadian Cancer Trials Group phase III trials (ONLINE)

Clinical Trials : 17407745211005045, 2021
Cheung MC;Chan KK;Golden S;Hay A;Pater J;Prica A;Chen BE;Leighl N;Mittmann N;

More >>

Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial

Am J Hematol 96: 552 - 560, 2021
Venner CP;LeBlanc R;Sandhu I;White D;Belch AR;Reece DE;Chen C;Dolan S;Lalancette M;Louzada M;Kew A;McCurdy A;Monteith B;Reiman T;McDonald G;Sherry M;Gul E;Chen BE;Hay AE;

More >>

Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.

J Clin Oncol 39, 2021
Pal SK;Tangen C;Thompson IM;Haas NB;George DJ;Heng DYC;Shuch BM;Stein MN;Tretiakova MS;Humphrey P;Adeniran A;Narayan V;Bjarnason GA;Vaishampayan UN;Alva AS;Zhang T;Cole SW;Plets M;Wright J;Lara PLN;

More >>